其中，公司核心产品TY-9591是第三代EGFR-TKI，是一款奥西替尼的氘代药物，主要用于治疗EGFR突变的非小细胞肺癌。该药物在前期临床试验中展现了极大的潜力，根据Ib期及II期临床研究的29例初治可评估非小细胞肺癌（NSCLC）脑转移患者临床数据，观察到25例患者达到颅内部分缓解（PR）及4例患者达到完全缓解（CR），颅内客观缓解率（ORR）为100%。The day after the listing of Tongyuan Kang Medical-B (02410), the stock rose by more than 22%, reaching a high of 16.82 Hong Kong dollars, an increase of more than 39% compared to the offering price of 12.1 Hong Kong dollars. As of the time of publication, it has risen by 20.58% to 16.52 Hong Kong dollars, with a turnover of 8.8934 million Hong Kong dollars.
According to the financial news app ZhuTong Finance, the day after the listing of Tongyuan Kang Medical-B (02410), the stock rose by more than 22%, reaching a high of 16.82 Hong Kong dollars, an increase of more than 39% compared to the offering price of 12.1 Hong Kong dollars. As of the time of publication, it has risen by 20.58% to 16.52 Hong Kong dollars, with a turnover of 8.8934 million Hong Kong dollars.
It is reported that Tongyuan Kang Medical was established in 2017 and is a clinical-stage biopharmaceutical company focusing on small molecule drugs and other related innovative drug categories, dedicated to the discovery, development, and commercialization of differentiated targeted therapies, mainly addressing unmet medical needs in the field of oncology, especially in the area of lung cancer. Currently, the company has a pipeline of 11 candidate drugs, including TY-9591 (core product), 6 clinical-stage products (including the key product TY-302 and internally developed key product TY-2136b), and 4 preclinical stage products.
Among them, the company's core product TY-9591 is a third-generation EGFR-TKI, which is a deuterated drug of osimertinib, mainly used to treat EGFR-mutated non-small cell lung cancer. The drug has shown great potential in early clinical trials. According to the clinical data of 29 evaluable NSCLC brain metastases patients in phase Ib and II clinical studies, partial remission (PR) was observed in 25 patients and complete remission (CR) in 4 patients, with an objective remission rate (ORR) of 100% for intracranial lesions.
